- The U.S. Patent and Trademark Office issues a Notice of Allowance to BioDelivery Sciences International's (NASDAQ:BDSI) patent application, that once formally granted, will be Orange Book listed and will extend the exclusivity of BELBUCA (buprenorphine) buccal film from July 2027 to December 2032.
- The patent covers the method of using BioErodible MucoAdhesive for the treatment of chronic pain.
- Shares are up 9% premarket on light volume.
BioDelivery Sciences announces notice of allowance of patent strengthening on BELBUCA to 2032
Recommended For You
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BDSI | - | - |
BioDelivery Sciences International, Inc. |